Findings

What do systematic reviews say?

45 questions · 45 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 31.1%GRADE not reported 0 · 0%Very low 12 · 26.7%Low 6 · 13.3%Moderate 3 · 6.7%High 10 · 22.2%

DPP‐4 inhibitors vs insulin glargine

Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

DPP‐4 inhibitors vs insulin glargine

Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

DPP‐4 inhibitors vs placebo

Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DPP‐4 inhibitors vs placebo

FBG (mmol/L) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 589 participants
Low

DPP‐4 inhibitors vs placebo

Death (all causes) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 4211 participants
Low

DPP‐4 inhibitors vs placebo

All cardiovascular death · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 5897 participants
Moderate

DPP‐4 inhibitors vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 210 participants
Moderate

DPP‐4 inhibitors vs placebo

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Very low

DPP‐4 inhibitors vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1443 participants
Very low

DPP‐4 inhibitors vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1257 participants
Very low

DPP‐4 inhibitors vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 867 participants
Low

Intervention not reported

Morbidity · type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Change in HbA1c from baseline to endpoint % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 6308 participants
High

Intervention not reported

Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus another single hypoglycaemic agent % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1764 participants
High

Intervention not reported

Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus placebo % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1139 participants
High

Intervention not reported

Change in body weight from baseline to endpoint ‐ Vildagliptin versus placebo kg ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 484 participants
High

Intervention not reported

Adverse events ‐ All‐cause infections ( · patients with type 2 diabetes mellitus

The intervention showed no clear difference in adverse events ‐ All‐cause infections ( (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
RR 1.04 [0.87, 1.24]
10 studies · 3573 participants
High

Intervention not reported

Health‐related quality of life · type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Change in HbA1c from baseline to endpoint % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 6907 participants
High

Intervention not reported

Change in HbA1c from baseline to endpoint ‐ Sitagliptin versus another single hypoglycaemic agent % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 592 participants
High